1.80

4.65% +0.08

After Hours: 1.8703 0.0703 +3.91%

Plus Therapeutics Inc (PSTV)

Overview News Price History Financials Discussions Forecast Stock Split

Plus Therapeutics Inc stock is currently priced at $1.80, with a 24-hour trading volume of 51,597. It has seen a +4.65% increased in the last 24 hours and a -3.74% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.74 pivot point. If it approaches the $1.81 resistance level, significant changes may occur.

Previous Close:

$1.72

Open:

$1.8

24h Volume:

51,597

Market Cap:

$7.84M

Revenue:

Net Income/Loss:

$-13.32M

P/E Ratio:

-0.299

EPS:

-6.02

Net Cash Flow:

$-13.01M

1W Performance:

+8.11%

1M Performance:

-3.74%

6M Performance:

+32.35%

1Y Performance:

-51.35%

1D Range:

$1.78

$1.92

52W Range:

$0.9694

$5.09

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name

Plus Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

737 255 7194

Address

4200 Marathon Boulevard, Suite 200, Austin, TX

Employee

Twitter

@plustxinc

Next Earnings Date

2024-04-29

Latest SEC Filings

PSTV's Discussions on Twitter

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-25-21	Initiated	Ladenburg Thalmann	Buy
Oct-16-20	Initiated	Maxim Group	Buy

Plus Therapeutics Inc Stock (PSTV) Latest News

Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates

Zacks Investment Research

Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

GlobeNewswire Inc.

Plus Therapeutics Inc Stock (PSTV) Financials Data

Plus Therapeutics Inc (PSTV) Net Income 2024

PSTV net income (TTM) was -$13.32 million for the quarter ending December 31, 2023, a +34.32% increase year-over-year.

Plus Therapeutics Inc (PSTV) Cash Flow 2024

PSTV recorded a free cash flow (TTM) of -$13.01 million for the quarter ending December 31, 2023, a +5.24% increase year-over-year.

Plus Therapeutics Inc (PSTV) Earnings per Share 2024

PSTV earnings per share (TTM) was -$4.39 for the quarter ending December 31, 2023, a +62.22% growth year-over-year.

Plus Therapeutics Inc Stock (PSTV) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Lenk Robert P	Director	Nov 16 '23	Buy	1.95	1,000	1,950	25,160
Lenk Robert P	Director	Nov 15 '23	Buy	1.77	1,000	1,770	24,160
Lenk Robert P	Director	Nov 13 '23	Buy	1.43	4,000	5,720	23,160
Lenk Robert P	Director	Nov 10 '23	Buy	1.45	2,000	2,900	19,160
Lenk Robert P	Director	Nov 09 '23	Buy	1.59	4,199	6,676	17,160
Lenk Robert P	Director	Nov 08 '23	Buy	1.65	5,000	8,250	12,961
Lenk Robert P	Director	Nov 07 '23	Buy	1.64	6,000	9,840	7,961
Lenk Robert P	Director	Nov 06 '23	Buy	1.50	1,395	2,092	1,961
Clowes Howard	Director	Sep 13 '23	Buy	1.43	6,993	10,022	11,693
Petersen Greg	Director	Sep 11 '23	Buy	1.70	20,000	34,062	24,166

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.